California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts

California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts

The New York Times - Business:

The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.

This post first appeared in The New York Times - Business. Read the original article.